SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Raymond Clutts who wrote ()3/30/2000 5:53:00 AM
From: wl9839  Read Replies (1) of 746
 
Takeda signs contract on use of Celera's gene data

Reuters Company News - March 30, 2000 02:19

TOKYO, March 30 (Reuters) - Major Japanese drug manufacturer Takeda Chemical
Industries Ltd said on Thursday it had signed a contract with the U.S. PE Corp on use of its
human genome information database.

The database is run by it Maryland-based unit Celera Genomics . Celera is one of several
private companies that plan to patent and otherwise license their information on human genes
for profit.

The five-year contract means Takeda can use Celera's database for a variety of gene data,
including that of human beings.

Celera had been in talks to enter into partnership with a publicly funded team of international
researchers working on the Human Genome Project, but the talks appeared to fall apart in
March over its demands to retain exclusive commercial rights to distribution of any merged
projects.

Celera's shares tumbled on March 14 on news U.S. President Bill Clinton and British Prime
Minister Tony Blair announced scientists around the world should have free access to research
on the mapping of human genes. PE Corp comprises two operating groups -- Celera Genomics
and California-based PE Biosystems Group .

News on the Takeda-PE Corp contract was released after the Tokyo stock market closed.
Takeda ended down 70 yen or 0.97 percent at 7,130 on the day. Copyright 2000 Reuters Limited. All
rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of
Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News